The UBE2A antibody is a crucial tool in studying the ubiquitin-conjugating enzyme E2A (UBE2A), a member of the E2 ubiquitin-conjugating enzyme family. UBE2A, also known as RAD6A, plays a pivotal role in the ubiquitin-proteasome system by transferring ubiquitin to target proteins, marking them for degradation or functional modification. This enzyme is involved in critical cellular processes, including DNA damage repair, transcriptional regulation, and cell cycle control. Dysregulation of UBE2A has been linked to neurological disorders, such as X-linked intellectual disability (XLID), and certain cancers, highlighting its importance in maintaining genomic stability and cellular homeostasis.
UBE2A antibodies are widely used in research to detect and quantify UBE2A protein expression, assess post-translational modifications, and investigate its interactions with substrates like RAD18 in DNA repair pathways. These antibodies are essential in techniques such as Western blotting, immunohistochemistry, immunofluorescence, and co-immunoprecipitation. Specificity and validation across species (e.g., human, mouse) are critical for reliable experimental outcomes. Recent studies also explore UBE2A's role in neurodegenerative diseases and cancer progression, making its antibody a valuable resource for uncovering molecular mechanisms and potential therapeutic targets. Researchers prioritize antibodies with high affinity, minimal cross-reactivity, and compatibility with diverse experimental models to ensure robust reproducibility.